Literature DB >> 2993900

Nonrandom loss of chromosome 15 in Syrian hamster tumours induced by v-Ha-ras plus v-myc oncogenes.

M Oshimura, T M Gilmer, J C Barrett.   

Abstract

Nonrandom chromosome rearrangements, observed in a variety of human and animal tumours, are associated in some cases with enhanced expression or deregulation of cellular oncogenes. Recently, it was shown that normal, diploid rodent cells are neoplastically transformed following transfection with two cooperating oncogenes, for example myc plus ras. However, the number of steps necessary to convert a normal cell into a malignant cell is unknown. If activation of two oncogenes is sufficient for tumorigenicity, tumours derived from diploid cells transformed by the transfected oncogenes may remain diploid or have only random chromosome alterations. We have performed cytogenetic analyses of tumours formed after transfection of Syrian hamster embryo cells with either v-Ha-ras plus v-myc DNAs or polyoma DNA alone. Whereas polyoma-induced, tumour-derived cells were diploid, tumours induced by v-Ha-ras plus v-myc oncogenes were monoclonal and had a nonrandom chromosome change, monosomy of chromosome 15. Thus, an additional change, loss of chromosome 15, is required for or is advantageous for tumorigenicity induced by v-Ha-ras plus v-myc oncogenes. These results suggest that the neoplastic progression of normal, diploid cells requires more than two steps under certain conditions.

Entities:  

Mesh:

Year:  1985        PMID: 2993900     DOI: 10.1038/316636a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  26 in total

1.  Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 3T3 cells.

Authors:  N Kuzumaki; Y Ogiso; A Oda; H Fujita; H Suzuki; C Sato; L Müllauer
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

2.  Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells.

Authors:  D Dedera; W Hu; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

3.  In vitro mRNA degradation system to study the virion host shutoff function of herpes simplex virus.

Authors:  C R Krikorian; G S Read
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  Assignment of the mu-class glutathione S-transferase gene (hGSTYBX) to Syrian hamster chromosome 15 by FISH.

Authors:  F Maggouta; S A Li; J J Li; J S Norris
Journal:  Mamm Genome       Date:  1996-06       Impact factor: 2.957

5.  Cooperative transforming activities of ras, myc, and src viral oncogenes in nonestablished rat adrenocortical cells.

Authors:  A MacAuley; T Pawson
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

6.  Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes.

Authors:  M Noda; H Kitayama; T Matsuzaki; Y Sugimoto; H Okayama; R H Bassin; Y Ikawa
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

7.  Regulation of c-myc mRNA stability in vitro by a labile destabilizer with an essential nucleic acid component.

Authors:  G Brewer; J Ross
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

8.  Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.

Authors:  X Wu; H Liu; H Xiao; J A Conway; J C Kappes
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Overlapping loss of heterozygosity by mitotic recombination on mouse chromosome 7F1-ter in skin carcinogenesis.

Authors:  A B Bianchi; N M Navone; C M Aldaz; C J Conti
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

Review 10.  Cellular proliferation and lipid metabolism: importance of lipoxygenases in modulating epidermal growth factor-dependent mitogenesis.

Authors:  T E Eling; W C Glasgow
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.